Alternatives to Liver Transplant: What Can Be Treated First, and What Cannot
There are real alternatives to liver transplant, but only when the problem is treatable: suppressing hepatitis B, curing hepatitis C, stopping alcohol, TIPS for portal hypertension, or treating Budd-Chiari syndrome. In a randomised trial, a covered-stent TIPS kept 93% of patients with recurrent ascites alive without a transplant at one year, against 52% with repeated paracentesis. Nothing yet reverses established liver failure except a new liver.
— Dr Chetan Kalal, DM Hepatology, Gleneagles Hospital Mumbai
Key takeaways
- Whether a transplant can be avoided depends entirely on why the liver is failing. Treat the cause — virus, alcohol, autoimmunity, a blocked vein — and a proportion of patients “recompensate”, a concept Baveno VII formally recognised in 2022.
- Paracentesis, band ligation and TIPS are bridges. They control a complication and buy time; they do not remove cirrhosis. “The ascites is controlled” is not the same as “the transplant is no longer needed”.
- TIPS has randomised-trial evidence behind it: early TIPS cut one-year mortality from 39% to 14% in high-risk variceal bleeders, and covered-stent TIPS raised one-year transplant-free survival from 52% to 93% in recurrent ascites. It remains a procedure for selected patients.
- Budd-Chiari syndrome is the classic transplant referral that often needs something else first. In a 157-patient European cohort managed step by step, only 20 ever required a transplant.
- Stem-cell infusions, herbal preparations and treatments sold abroad have no proven role; the only adequately powered stem-cell trial showed no benefit and more serious adverse events. The danger is not that they fail but that they consume the window in which a transplant was still possible.
“Doctor, is there anything else we can do instead of a transplant?” Sometimes, yes — but it depends entirely on why the patient needs a transplant and how advanced the disease has become.
Transplantation isn’t the automatic answer to every case of advanced liver disease. Before recommending it, the real question is what can still be treated, what can be controlled, and whether treating the underlying disease can meaningfully change the trajectory. At the same time, a patient with a clear transplant indication shouldn’t lose valuable time chasing treatments that can’t reverse irreversible liver failure. This article is about telling those two situations apart. It is educational, not a prescription: never start, stop or alter any medicine on the strength of something you read here — the decision belongs with the team that has your reports.
What gets tried before transplant
Treatment depends entirely on the disease and its complications. For decompensated cirrhosis, the EASL 2018 guideline and the Baveno VII consensus set out the sequence, and in practice it means aggressive management of:
- Ascites — sodium restriction, appropriate diuretics, therapeutic paracentesis with albumin, and in selected patients a TIPS. My post on ascites in cirrhosis covers the steps.
- Hepatic encephalopathy — identifying and treating the precipitating factor (infection, bleeding, constipation, a sedative, dehydration) alongside appropriate medical therapy.
- Variceal bleeding — endoscopic band ligation plus portal-pressure-lowering drugs, and in high-risk patients a pre-emptive TIPS within days of the bleed. See variceal bleeding treatment.
- Hepatorenal dysfunction — early recognition, volume assessment, vasoconstrictor therapy and organ support.
- Recurrent or refractory complications — considering TIPS (transjugular intrahepatic portosystemic shunt) in carefully selected patients.
When there’s a disease-specific treatment, that matters more than any of the above. Antiviral therapy can dramatically change the trajectory for some patients with viral hepatitis — hepatitis B can usually be suppressed long-term with a single daily tablet, and EASL’s guideline asks that every cirrhotic patient with detectable virus be treated; hepatitis C is now curable with direct-acting antivirals in the great majority. Alcohol-related disease responds to one intervention above all others, which is abstinence. Autoimmune and cholestatic liver diseases each need their own disease-specific management. Whether a damaged liver can recover once the insult stops is the subject of my post on liver regeneration.
The real question isn’t “can we treat the liver disease?” It’s: can treatment change the patient’s long-term outcome enough to make transplant unnecessary — or are we simply buying time until transplantation?
A bridge is not the same as a cure
This distinction matters enormously. Some treatments are bridges to transplant — they control a complication and buy time, without meaning the underlying disease has disappeared. Repeated paracentesis may control severe ascites. Band ligation reduces variceal bleeding risk. TIPS can be genuinely valuable in the right patient.
TIPS deserves a word, because families often hear about it as a way of “avoiding the operation”. It is a stent placed through the liver to divert portal blood into the systemic circulation, lowering portal pressure. Two randomised trials define where it earns its place. In 63 patients with cirrhosis and acute variceal bleeding at high risk of failure, García-Pagán and colleagues showed that a covered-stent TIPS placed within 72 hours, rather than held back as rescue, raised one-year survival from 61% to 86%. In 62 patients needing repeated large-volume paracentesis, Bureau and colleagues showed that a covered TIPS kept 93% alive without transplant at one year, versus 52% with paracentesis and albumin — with ten times fewer taps and half the days in hospital. Baveno VII built both findings into its recommendations. Yet in neither trial did TIPS cure cirrhosis. It bought time and quality of life, at the price of a higher encephalopathy risk in some patients, and it is unsuitable where liver function is already very poor. That is why selection is everything.
Families sometimes hear “the ascites is controlled” and assume the transplant might no longer be necessary. Not necessarily — we have to look at the overall trajectory, not one controlled symptom.
When treatment can actually avoid transplant
Some patients genuinely change course. Baveno VII gave this a name — recompensation — and a definition: the cause of the cirrhosis has been removed or suppressed, the complications (ascites, encephalopathy, bleeding) have resolved and stayed away without the drugs used to control them, and liver function has measurably improved. It happens most often in alcohol-related cirrhosis after sustained abstinence, in hepatitis B once the virus is suppressed, and in hepatitis C after cure. It does not happen in everyone. In an analysis of 622 patients with decompensated hepatitis C cirrhosis treated with direct-acting antivirals, those with ascites or encephalopathy, a low albumin or a higher body mass index were far less likely to climb back to Child-Pugh A even when the virus was cleared — the liver had passed the point where removing the insult was enough.
That’s why not every patient goes straight onto a transplant pathway without first asking if something reversible remains. But the opposite mistake is equally dangerous: assuming every case of advanced liver disease has a medical alternative to transplant. Sometimes it doesn’t.
Problem by problem: bridge, cure, or neither
| Problem | Bridge or disease-specific treatment | Can it avoid transplant? |
|---|---|---|
| Recurrent or refractory ascites | Diuretics, salt restriction, large-volume paracentesis with albumin; covered-stent TIPS in selected patients | Sometimes delays it substantially — 93% one-year transplant-free survival with TIPS in the Bureau trial — but the cirrhosis remains. Refractory ascites is itself a listing indication. |
| Variceal bleeding | Band ligation plus non-selective beta-blockers; pre-emptive TIPS within 72 hours in high-risk bleeders | Prevents death from bleeding; does not treat the liver. Recurrent bleeding despite therapy points towards transplant. |
| Hepatic encephalopathy | Treat the precipitant; medical therapy; nutrition | Controls episodes. Recurrent or persistent encephalopathy is a decompensating event that counts in favour of transplant. |
| Hepatitis B cirrhosis | Long-term oral antiviral suppression (EASL: treat all cirrhotics with detectable virus) | Yes, in a proportion — recompensation is well described. Decompensated patients are treated and listed in parallel until the trajectory is clear. |
| Hepatitis C cirrhosis | Direct-acting antivirals | Yes, in some. Those with ascites, encephalopathy or very low albumin are less likely to recover despite cure (El-Sherif 2018). Cure before transplant also simplifies what follows. |
| Alcohol-related cirrhosis | Complete, sustained abstinence with addiction support; nutrition | Yes, often — the single most powerful “alternative” there is. See alcohol-related liver disease. |
| Budd-Chiari syndrome | Anticoagulation → angioplasty or stenting of the blocked vein → TIPS → transplant only if these fail (EASL 2016 step-wise approach) | Usually. In 157 European patients followed for a median of 50 months, 62 needed a TIPS and only 20 a transplant. |
| Acute liver failure (e.g. hepatitis A or E, paracetamol, drug injury) | Intensive-care support; cause-specific therapy; serial reassessment against transplant criteria | Some recover spontaneously, especially paracetamol and hepatitis A. Once prognostic criteria are met, waiting kills; transplant is the treatment. |
| Liver cancer in cirrhosis | Ablation, resection, chemo-embolisation or systemic therapy depending on stage | Depends on stage and liver function; transplant treats both the cancer and the cirrhosis. See HCC staging and treatment. |
| Stem-cell infusion, herbal or “liver detox” products | — | No. The only adequately powered randomised trial (REALISTIC, 81 patients) found no improvement in liver function and more serious adverse events. Several herbal products cause liver injury themselves. |
Case: the referral that turned out to be something else entirely
A young man was referred to us for living-donor liver transplant, with the initial impression of advanced liver disease requiring transplantation. During evaluation, we looked more closely at the underlying problem rather than accepting that initial label — and identified Budd-Chiari syndrome, obstruction of the veins draining the liver, as the actual driver.
That changed everything. Budd-Chiari is a vascular disease wearing the clothes of cirrhosis, and EASL’s guideline on vascular liver disease asks for a step-wise approach — anticoagulation, then reopening the blocked vein where possible, then TIPS, with transplant reserved for those who fail. Instead of proceeding toward transplant, we considered whether his portal hypertension and hepatic venous outflow problem could be managed with a TIPS-based strategy. He underwent that management, and transplantation was deferred.
This is exactly why not every patient referred for transplant should automatically proceed to one. The question isn’t “can we perform a transplant?” — it’s “does this patient need a transplant now, and is it actually the best treatment?” A potentially treatable vascular disorder shouldn’t become an automatic transplant indication just because the patient initially looked like a standard advanced-liver-disease case. Sometimes the most important part of a transplant evaluation is discovering the patient needs something else first.
Case: when observation was right — until it wasn’t
The reverse situation happens too. A male patient with hepatitis A and acute liver injury was initially sent for observation rather than immediate transplant consideration — reasonable, given the clinical picture at that point, and consistent with the fact that most adults with hepatitis A recover. But acute liver disease can move fast. He went on to develop acute liver failure, and at that point continued observation was no longer sufficient — transplantation became necessary.
This doesn’t mean the first decision was wrong. It means the disease trajectory changed. In acute liver failure especially, serial reassessment is critical — neurological status, coagulation, kidney function, haemodynamics and biochemical profile can shift substantially over a short window, and the EASL guideline is built around exactly this: early contact with a transplant centre, repeated scoring against transplant criteria, and transfer before the patient is too unstable to move. The transplant team stays involved even when transplant isn’t immediately indicated, precisely because that can change quickly.
Two cases, one lesson
Transplant considered → diagnosis clarified → TIPS-based management → transplant deferred.
Observation appropriate → clinical deterioration → acute liver failure → transplant became necessary.
Opposite outcomes, same underlying principle: transplantation should be driven by the patient’s disease, trajectory and expected benefit — not by the fact that someone has been referred for one. Transplant evaluation is not a commitment to surgery. It’s an opportunity to understand exactly where a patient stands. Sometimes that means “we should transplant.” Sometimes “we should optimise and wait.” Sometimes “there’s another treatment to try first.” And sometimes “the patient has deteriorated, and we can’t safely wait any longer.” The skill is recognising which situation is in front of you — and noticing when the answer changes.
When families keep searching for an alternative
This is where conversations get difficult. Families understandably want to avoid transplant, and may ask about a new medicine, a herbal treatment, stem-cell therapy, a procedure read about online, or treatment available abroad. Their concerns aren’t dismissed — but one question always gets asked: is this treatment actually capable of reversing the patient’s liver failure, or is it simply delaying a decision we already know we need to make?
On stem cells, the evidence is plain. The REALISTIC trial in the United Kingdom randomised 81 patients with cirrhosis to standard care, to a bone-marrow-mobilising drug, or to that drug plus three infusions of their own stem cells. Liver function did not improve in either treatment arm, and serious adverse events — sepsis, encephalopathy, worsening ascites — were about four times as frequent in the stem-cell group as with standard care. No herbal preparation has been shown in a controlled trial to reverse cirrhosis, and a number of them are recognised causes of liver injury in their own right. If a clinic offers you either as a substitute for transplant, that is the moment to seek a second opinion, not to book a flight.
That distinction can be life-changing. If transplant is indicated and a patient keeps searching for an unproven alternative, the real danger isn’t just that the alternative doesn’t work — it’s that the patient may lose the window in which transplant was still safely possible.
The opposite mistake: transplanting too early
A patient shouldn’t be sent toward transplant simply because a scan is abnormal or cirrhosis has been diagnosed. What matters: is the disease compensated or decompensated, what complications have occurred, what’s the trajectory, is there a disease-specific treatment, can complications be controlled, what’s the expected benefit of transplant, and is the patient fit enough for it. A compensated cirrhotic with a low MELD score and a treatable cause stands to lose more than gain from an operation today.
Sometimes the honest answer is “we don’t need to transplant you today — we need to treat you, monitor you closely, and prepare for transplant if the disease progresses.” That’s very different from telling a patient transplant is unnecessary altogether.
Why early evaluation, not late referral
Being evaluated for transplant and having a transplant immediately are not the same thing. Assessing a patient early, understanding trajectory, optimising their condition and preparing appropriately is far better than meeting them for the first time critically ill with multiple organ complications. Early evaluation gives options — treating complications, improving nutrition and fitness, addressing infections or other contraindications, completing the work-up, and involving the family in the decision. Sometimes the patient improves and doesn’t need transplant immediately. That’s still a successful outcome.
The rule of thumb
Not “can we somehow avoid a transplant?” but “what is the best treatment for this patient at this stage of the disease?” Sometimes that’s medical treatment. Sometimes it’s a procedure like TIPS in the right patient. Sometimes it’s continued surveillance and optimisation. And sometimes, honestly, it’s: “we’ve reached the point where transplantation offers the best chance of meaningful long-term survival.” Once that point is reached, fear of transplant shouldn’t push a patient toward ineffective alternatives.
The right alternative to transplantation is a treatment that genuinely changes the patient’s prognosis — not simply one that postpones an inevitable decision.
Frequently asked questions
If my symptoms are controlled with medication, does that mean I don’t need a transplant?
Not necessarily. Controlling a symptom like ascites doesn’t mean the underlying disease has resolved. The overall trajectory — liver function over months, further decompensating events, whether the cause has been removed — matters more than any single controlled complication.
Is TIPS a substitute for a liver transplant?
No. TIPS manages specific complications of portal hypertension — recurrent ascites, high-risk variceal bleeding — and in randomised trials it improved survival in those settings. It does not cure the underlying liver disease, it can worsen encephalopathy, and it is unsuitable when liver function is already very poor. In the right patient it is a bridge; in some, a long one.
If I’m referred for transplant evaluation, does that mean surgery is inevitable?
No. Evaluation often clarifies the diagnosis and trajectory, and can lead to deferral, continued monitoring or alternative treatment rather than automatic surgery — as the Budd-Chiari case above shows.
Can treating hepatitis B or C avoid a liver transplant?
In a proportion of patients, yes. Suppressing hepatitis B or curing hepatitis C removes the injury, and some decompensated patients recompensate — Baveno VII now defines this formally. Those who already have ascites, encephalopathy or very low albumin are less likely to recover enough, so treatment and transplant evaluation proceed in parallel until the direction is clear.
Do stem-cell or herbal treatments work as an alternative to liver transplant?
No proven role. The only adequately powered randomised trial of stem-cell therapy in cirrhosis showed no improvement in liver function and more serious adverse events. No herbal product has been shown to reverse cirrhosis, and several cause liver injury. The real cost of trying them is the time lost while a transplant is still possible.
What is Budd-Chiari syndrome, and can it be treated without a transplant?
Budd-Chiari syndrome is obstruction of the veins that drain blood out of the liver, usually from a clotting tendency. It mimics cirrhosis but is treated step by step — anticoagulation, reopening the blocked vein, TIPS — with transplant reserved for the minority in whom these fail. In a 157-patient European cohort, only 20 ultimately needed a transplant.
Book a consultation with Dr Chetan Kalal at Gleneagles Hospital, Mumbai — call +91 83294 76669 or use the appointment form on this site. International and NRI patients may request a teleconsultation.
References
- de Franchis R, Bosch J, Garcia-Tsao G, Reiberger T, Ripoll C; Baveno VII Faculty. Baveno VII — Renewing consensus in portal hypertension. J Hepatol. 2022;76(4):959–974. PMID 35120736. doi:10.1016/j.jhep.2021.12.022
- European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018;69(2):406–460. PMID 29653741. doi:10.1016/j.jhep.2018.03.024
- European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Vascular diseases of the liver. J Hepatol. 2016;64(1):179–202. PMID 26516032. doi:10.1016/j.jhep.2015.07.040
- European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370–398. PMID 28427875. doi:10.1016/j.jhep.2017.03.021
- European Association for the Study of the Liver. EASL Clinical Practical Guidelines on the management of acute (fulminant) liver failure. J Hepatol. 2017;66(5):1047–1081. PMID 28417882. doi:10.1016/j.jhep.2016.12.003
- García-Pagán JC, Caca K, Bureau C, et al. Early use of TIPS in patients with cirrhosis and variceal bleeding. N Engl J Med. 2010;362(25):2370–2379. PMID 20573925. doi:10.1056/NEJMoa0910102
- Bureau C, Thabut D, Oberti F, et al. Transjugular intrahepatic portosystemic shunts with covered stents increase transplant-free survival of patients with cirrhosis and recurrent ascites. Gastroenterology. 2017;152(1):157–163. PMID 27663604. doi:10.1053/j.gastro.2016.09.016
- Seijo S, Plessier A, Hoekstra J, et al. Good long-term outcome of Budd-Chiari syndrome with a step-wise management. Hepatology. 2013;57(5):1962–1968. PMID 23389867. doi:10.1002/hep.26306
- El-Sherif O, Jiang ZG, Tapper EB, et al. Baseline factors associated with improvements in decompensated cirrhosis after direct-acting antiviral therapy for hepatitis C virus infection. Gastroenterology. 2018;154(8):2111–2121.e8. PMID 29535028. doi:10.1053/j.gastro.2018.03.022
- Newsome PN, Fox R, King AL, et al. Granulocyte colony-stimulating factor and autologous CD133-positive stem-cell therapy in liver cirrhosis (REALISTIC): an open-label, randomised, controlled phase 2 trial. Lancet Gastroenterol Hepatol. 2018;3(1):25–36. PMID 29127060. doi:10.1016/S2468-1253(17)30326-6
